(BCHN) Burckhardt Compression - Ratings and Ratios
Exchange: SW •
Country: Switzerland •
Currency: CHF •
Type: Common Stock •
ISIN: CH0025536027
Industrial Compressors, Systems, Components
Description: BCHN Burckhardt Compression
Burckhardt Compression (SW:BCHN) is a Swiss industrial machinery company with a market capitalization of approximately 2.46 billion CHF. The companys stock has demonstrated a strong performance, with a current price of 726.00 CHF, near its 52-week high.
Key performance indicators suggest a robust financial position, with a return on equity (RoE) of 67.45%, indicating efficient use of shareholder capital. The price-to-earnings (P/E) ratio of 23.25 and forward P/E of 22.88 imply a relatively stable earnings outlook, with potential for continued growth.
The industrial machinery sector is closely tied to economic drivers such as global manufacturing output, infrastructure spending, and energy demand. As a supplier of compression solutions, Burckhardt Compression is likely exposed to trends in the oil and gas, chemical, and power generation industries. The companys beta of 0.918 suggests a relatively low volatility profile compared to the broader market.
To further evaluate the investment potential of BCHN, it is essential to analyze the companys revenue growth, profit margins, and cash flow generation. Additionally, assessing the competitive landscape and industry trends will help identify potential risks and opportunities. Key metrics to monitor include the companys order backlog, sales pipeline, and research and development investments.
BCHN Stock Overview
| Market Cap in USD | 3,015m |
| Sub-Industry | Industrial Machinery & Supplies & Components |
| IPO / Inception |
BCHN Stock Ratings
| Growth Rating | 77.6% |
| Fundamental | 83.2% |
| Dividend Rating | 74.7% |
| Total Return vs S&P 500 | 8.07% |
| Analyst Rating | - |
BCHN Dividends
| Dividend Yield 12m | 2.69% |
| Yield on Cost 5y | 8.96% |
| Annual Growth 5y | 20.90% |
| Payout Consistency | 94.6% |
| Payout Ratio | 57.7% |
BCHN Growth Ratios
| Growth Correlation 3m | 92.2% |
| Growth Correlation 12m | 37.1% |
| Growth Correlation 5y | 94.1% |
| CAGR 5y | 28.94% |
| CAGR/Max DD 5y | 0.96 |
| Sharpe Ratio 12m | 1.38 |
| Alpha | 11.48 |
| Beta | 0.775 |
| Volatility | 23.21% |
| Current Volume | 3.7k |
| Average Volume 20d | 4.2k |
| Stop Loss | 696.4 (-3%) |
| Signal | -0.37 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (195.6m TTM) > 0 and > 6% of Revenue (6% = 124.7m TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA 1.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 15.53% (prev 17.46%; Δ -1.94pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 230.6m > Net Income 195.6m (YES >=105%, WARN >=100%) |
| Net Debt (-213.4m) to EBITDA (298.3m) ratio: -0.72 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.38m) change vs 12m ago 0.37% (target <= -2.0% for YES) |
| Gross Margin 27.36% (prev 29.46%; Δ -2.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 197.1% (prev 132.3%; Δ 64.80pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 38.13 (EBITDA TTM 298.3m / Interest Expense TTM 6.73m) >= 6 (WARN >= 3) |
Altman Z'' 4.85
| (A) 0.28 = (Total Current Assets 961.7m - Total Current Liabilities 639.1m) / Total Assets 1.17b |
| (B) 0.29 = Retained Earnings (Balance) 341.1m / Total Assets 1.17b |
| (C) 0.24 = EBIT TTM 256.8m / Avg Total Assets 1.05b |
| (D) 0.42 = Book Value of Equity 349.6m / Total Liabilities 827.2m |
| Total Rating: 4.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.19
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 7.83% = 3.92 |
| 3. FCF Margin 8.94% = 2.24 |
| 4. Debt/Equity 0.48 = 2.39 |
| 5. Debt/Ebitda 0.54 = 2.28 |
| 6. ROIC - WACC 58.39% = 12.50 |
| 7. RoE 67.45% = 2.50 |
| 8. Revenue Trend data missing |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 74.93% = 1.87 |
| 11. EPS CAGR 62.20% = 2.50 |
What is the price of BCHN shares?
As of August 19, 2025, the stock is trading at CHF 718.00 with a total of 3,675 shares traded.
Over the past week, the price has changed by -0.69%, over one month by +2.43%, over three months by +18.70% and over the past year by +25.78%.
Over the past week, the price has changed by -0.69%, over one month by +2.43%, over three months by +18.70% and over the past year by +25.78%.
Is Burckhardt Compression a good stock to buy?
Yes, based on ValueRay´s Fundamental Analyses, Burckhardt Compression (SW:BCHN) is currently (August 2025)
a good stock to buy. It has a ValueRay Fundamental Rating of 83.19 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCHN is around 816.95 CHF . This means that BCHN is currently undervalued and has a potential upside of +13.78% (Margin of Safety).
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCHN is around 816.95 CHF . This means that BCHN is currently undervalued and has a potential upside of +13.78% (Margin of Safety).
Is BCHN a buy, sell or hold?
Burckhardt Compression has no consensus analysts rating.
What are the forecasts/targets for the BCHN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 728 | 1.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 909.7 | 26.7% |
BCHN Fundamental Data Overview
Market Cap USD = 3.02b (2.43b CHF * 1.2389 CHF.USD)
Market Cap CHF = 2.43b (2.43b CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 222.9m CHF (last quarter)
P/E Trailing = 22.9907
P/E Forward = 22.8833
P/S = 2.2213
P/B = 7.1409
Beta = 0.906
Revenue TTM = 2.08b CHF
EBIT TTM = 256.8m CHF
EBITDA TTM = 298.3m CHF
Long Term Debt = 152.5m CHF (from longTermDebt, last quarter)
Short Term Debt = 9.55m CHF (from shortTermDebt, last quarter)
Debt = 162.0m CHF (Calculated: Short Term 9.55m + Long Term 152.5m)
Net Debt = -213.4m CHF (from netDebt column, last quarter)
Enterprise Value = 2.37b CHF (2.43b + Debt 162.0m - CCE 222.9m)
Interest Coverage Ratio = 38.13 (Ebit TTM 256.8m / Interest Expense TTM 6.73m)
FCF Yield = 7.83% (FCF TTM 185.8m / Enterprise Value 2.37b)
FCF Margin = 8.94% (FCF TTM 185.8m / Revenue TTM 2.08b)
Net Margin = 9.41% (Net Income TTM 195.6m / Revenue TTM 2.08b)
Gross Margin = 27.36% ((Revenue TTM 2.08b - Cost of Revenue TTM 1.51b) / Revenue TTM)
Tobins Q-Ratio = 6.79 (Enterprise Value 2.37b / Book Value Of Equity 349.6m)
Interest Expense / Debt = 0.74% (Interest Expense 1.20m / Debt 162.0m)
Taxrate = 23.16% (from yearly Income Tax Expense: 31.8m / 137.5m)
NOPAT = 197.3m (EBIT 256.8m * (1 - 23.16%))
Current Ratio = 1.50 (Total Current Assets 961.7m / Total Current Liabilities 639.1m)
Debt / Equity = 0.48 (Debt 162.0m / last Quarter total Stockholder Equity 339.8m)
Debt / EBITDA = 0.54 (Net Debt -213.4m / EBITDA 298.3m)
Debt / FCF = 0.87 (Debt 162.0m / FCF TTM 185.8m)
Total Stockholder Equity = 289.9m (last 4 quarters mean)
RoA = 16.75% (Net Income 195.6m, Total Assets 1.17b )
RoE = 67.45% (Net Income TTM 195.6m / Total Stockholder Equity 289.9m)
RoCE = 58.04% (Ebit 256.8m / (Equity 289.9m + L.T.Debt 152.5m))
RoIC = 66.74% (NOPAT 197.3m / Invested Capital 295.6m)
WACC = 8.35% (E(2.43b)/V(2.60b) * Re(8.87%)) + (D(162.0m)/V(2.60b) * Rd(0.74%) * (1-Tc(0.23)))
Shares Correlation 5-Years: -50.0 | Cagr: -0.07%
Discount Rate = 8.87% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.02% ; FCFE base≈166.5m ; Y1≈173.9m ; Y5≈201.5m
Fair Price DCF = 900.0 (DCF Value 3.04b / Shares Outstanding 3.38m; 5y FCF grow 4.80% → 3.0% )
Revenue Correlation: N/A | Revenue CAGR: 0.0%
Revenue Growth Correlation: 13.43%
EPS Correlation: 74.93 | EPS CAGR: 62.20%
EPS Growth Correlation: 59.40%
Market Cap CHF = 2.43b (2.43b CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 222.9m CHF (last quarter)
P/E Trailing = 22.9907
P/E Forward = 22.8833
P/S = 2.2213
P/B = 7.1409
Beta = 0.906
Revenue TTM = 2.08b CHF
EBIT TTM = 256.8m CHF
EBITDA TTM = 298.3m CHF
Long Term Debt = 152.5m CHF (from longTermDebt, last quarter)
Short Term Debt = 9.55m CHF (from shortTermDebt, last quarter)
Debt = 162.0m CHF (Calculated: Short Term 9.55m + Long Term 152.5m)
Net Debt = -213.4m CHF (from netDebt column, last quarter)
Enterprise Value = 2.37b CHF (2.43b + Debt 162.0m - CCE 222.9m)
Interest Coverage Ratio = 38.13 (Ebit TTM 256.8m / Interest Expense TTM 6.73m)
FCF Yield = 7.83% (FCF TTM 185.8m / Enterprise Value 2.37b)
FCF Margin = 8.94% (FCF TTM 185.8m / Revenue TTM 2.08b)
Net Margin = 9.41% (Net Income TTM 195.6m / Revenue TTM 2.08b)
Gross Margin = 27.36% ((Revenue TTM 2.08b - Cost of Revenue TTM 1.51b) / Revenue TTM)
Tobins Q-Ratio = 6.79 (Enterprise Value 2.37b / Book Value Of Equity 349.6m)
Interest Expense / Debt = 0.74% (Interest Expense 1.20m / Debt 162.0m)
Taxrate = 23.16% (from yearly Income Tax Expense: 31.8m / 137.5m)
NOPAT = 197.3m (EBIT 256.8m * (1 - 23.16%))
Current Ratio = 1.50 (Total Current Assets 961.7m / Total Current Liabilities 639.1m)
Debt / Equity = 0.48 (Debt 162.0m / last Quarter total Stockholder Equity 339.8m)
Debt / EBITDA = 0.54 (Net Debt -213.4m / EBITDA 298.3m)
Debt / FCF = 0.87 (Debt 162.0m / FCF TTM 185.8m)
Total Stockholder Equity = 289.9m (last 4 quarters mean)
RoA = 16.75% (Net Income 195.6m, Total Assets 1.17b )
RoE = 67.45% (Net Income TTM 195.6m / Total Stockholder Equity 289.9m)
RoCE = 58.04% (Ebit 256.8m / (Equity 289.9m + L.T.Debt 152.5m))
RoIC = 66.74% (NOPAT 197.3m / Invested Capital 295.6m)
WACC = 8.35% (E(2.43b)/V(2.60b) * Re(8.87%)) + (D(162.0m)/V(2.60b) * Rd(0.74%) * (1-Tc(0.23)))
Shares Correlation 5-Years: -50.0 | Cagr: -0.07%
Discount Rate = 8.87% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.02% ; FCFE base≈166.5m ; Y1≈173.9m ; Y5≈201.5m
Fair Price DCF = 900.0 (DCF Value 3.04b / Shares Outstanding 3.38m; 5y FCF grow 4.80% → 3.0% )
Revenue Correlation: N/A | Revenue CAGR: 0.0%
Revenue Growth Correlation: 13.43%
EPS Correlation: 74.93 | EPS CAGR: 62.20%
EPS Growth Correlation: 59.40%